Andromeda Biotech Overview

  • Founded
  • 2007
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 8

Andromeda Biotech General Information

Description

Developer of a treatment for autoimmune diabetes. The company offers DiaPep277, a product for treating Type 1 diabetes (T1D). The company's product is a peptide that represents a therapeutic approach to prevent the destruction of insulin producing cells in the pancreas.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Primary Office
  • 42 Hayarkon Street
  • Industrial Area
  • Yavne 81227
  • Israel
+972 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Andromeda Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Andromeda Biotech‘s full profile, request access.

Request a free trial

Andromeda Biotech Executive Team (2)

Name Title Board Seat Contact Info
Shlomo Dagan Chief Executive Officer
Chaim Eldar Chief Financial Officer
To view Andromeda Biotech’s complete executive team members history, request access »

Andromeda Biotech Board Members (2)

Name Representing Role Since
0000 00000 Self Board Member 000 0000
00000 0000000 Self Board Member 000 0000
To view Andromeda Biotech’s complete board members history, request access »

Andromeda Biotech Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Andromeda Biotech‘s full profile, request access.

Request a free trial